FIELD: chemistry.
SUBSTANCE: proposed is a recombinant single-strand trispecific antibody for treating tumours which express CEA. The said antibody consists of a series of three antibody fragments: anti-CEA-scFv, anti-CD3-scFv and VH CD28-antibody, linked by two intermediate linkers (intermediate linker Fc and intermediate linker HSA). If necessary, a c-myc-mark or (His)6-mark can be added at the C-end. Described is DNA, which codes the antibody, expression vector based on it and E.coli cell, containing the vector.
EFFECT: use of the invention is more beneficial in clinical use compared to bispecific antibodies and known trispecific antibodies, makes easier clearing and expression of an antibody, which can further be used in treating CEA-mediated tumours.
10 cl, 21 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-STRANDED CYCLIC TRI-SPECIFIC ANTIBODY | 2002 |
|
RU2355705C2 |
| TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND USE THEREOF | 2016 |
|
RU2730605C2 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
| SOLUBLE CD3 STABLE PHARMACEUTICAL COMPOSITIONS | 2006 |
|
RU2426743C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY | 2013 |
|
RU2652880C2 |
| ANTIBODY FRAGMENTS SPECIFIC IN RELATION TO HUMAN CANCER-EMBRYONIC ANTIGEN (CEA) | 2003 |
|
RU2294939C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| SILENT ANTI-CD28-ANTIBODY AND THEIR APPLYING | 2001 |
|
RU2261723C2 |
| MONOCLONAL ANTIBODIES AND ONE-CHAIN FRAGMENTS OF CELL-SURFACE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODIES | 2006 |
|
RU2458073C2 |
| ANTI-VEGF-ANTIBODY AND ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION, DIAGNOSTICS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE | 2014 |
|
RU2644245C2 |
